Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of intravesical BH011 in BCG-failed high-risk non-muscle-invasive bladder cancer
CTR20220208Phase 2Active
- Sponsor
- Zhuhai Beihai Biotech
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BH011 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Zhuhai Beihai Biotech. Started Feb 2022; status: active.
02
Drugs
BH011
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20220208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220208.